In May 2010, Imarx Therapeutics, Inc. was acquired by Sycamore Films, Inc., in a reverse merger transaction. The acquiring firm - now trading OTC:SAGI - is in totally diferent space. Previously, the ImaRxhad focused on the research, development, and commercialization of therapies for stroke and other vascular disorders using its microbubble technology. Its lead program, SonoLysis, involved the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The firm had offered and then withdrew its IPO in 2006 but did not achieve full offering until 2007 and then for very small monies. The firm then felt victim to the 2008 collapse and was subsequently removed to OTC, During 2008, several of the firm's primary technology assets were bought by Microbix Biosystems. Finally, in 2013 the remnader of the firm was acquired by Cerevast Therapeutics - a company organized around treatments for acute ischemic stroke and other vascular disorders.
